贝伐单抗联合白蛋白结合型紫杉醇治疗复发性卵巢癌的临床观察

目的 比较贝伐单抗联合白蛋白结合型紫杉醇与贝伐单抗治疗卵巢癌的疗效及不良反应.方法 60例经病理组织学和(或)细胞学检查确诊的ⅢB期或Ⅳ期复发型卵巢癌患者,其中多伐单抗联合白蛋白结合型紫杉醇组(联合组)28例,贝伐单抗组32例,分别给予贝伐单抗联合白蛋白结合型紫杉醇和贝伐单抗方案进行4个周期的治疗.评估两种治疗方法的近期疗效和不良反应.结果 联合组和贝伐单抗组的疾病控制率分别为85.7％和81.2％,部分缓解率分别为46.4％和43.7％.贝伐单抗组OS为7.0个月,联合组OS为7.3个月;P=0.63.贝伐单抗组与联合组中性粒细胞减少发生率分别为50.0％和42.8％,3～4级白细胞减少发生率分别为43.8％和24.9％ (P=0.001),两组比较差异具统计学意义,血小板减少发生率分别为53.0％和25.0％,差异具有统计学意义.结论 贝伐单抗联合白蛋白结合型紫杉醇治疗复发型卵巢癌疗效良好,不良反应少,安全性更好.

Clinical Observation of Bevacizumab Combined with Albumin-conjugated Paclitaxel in the Treatment of Recurrent Ovarian Cancer

Objective To compare the efficacy and side effects of bevacizumab combined with albumin-binding paclitaxel and bevacizumab in the treatment of ovarian cancer.Methods 60 patients with stage Ⅱ or Ⅳ recurrent ovarian cancer diagnosed by histopathology and/or cytology were selected,including 28 cases treated with bevacizunab combined with albumin-binding paclitaxel (combined group),32 cases treated with bevacizumab (bevacizumab group),both groups received 4 cycles of treatment.To assess the short-term efficacy and side effects of both treatments.Results The control rates of combined group and bevacizumab group were 85.7％ and 81.2％,respectively,and the partial remission rates of combined group and bevacizunab group were 46.4％ and 43.7％,respectively.The OS was 7.0 mnonths in bevacizumab group and 7.3 months in combined group,P =0.63.The incidence of neutropenia in bevacizumab group and combined group were 50.0％ and 42.8％,respectively,and the incidence of leukopenia at grade 3 to 4 was 43.8％/24.9％ (P =0.001),respectively.The difference between the 2 groups was statistically significant,the incidence of thrombocytopenia were 53.0％ and 25.0％,the difference was statistically significant.Conclusion Bevacizumab combined with albumin-conjugated paclitaxel has a good effect,with less adverse reactions and higher safety in the treatment of recurrent ovarian cancer.